Jack Yvars v. AstraZeneca Pharmaceuticals LP

2025 DNH 019
CourtDistrict Court, D. New Hampshire
DecidedFebruary 19, 2025
Docket24-cv-237-SE
StatusPublished

This text of 2025 DNH 019 (Jack Yvars v. AstraZeneca Pharmaceuticals LP) is published on Counsel Stack Legal Research, covering District Court, D. New Hampshire primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jack Yvars v. AstraZeneca Pharmaceuticals LP, 2025 DNH 019 (D.N.H. 2025).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE

Jack Yvars

v. Case No. 24-cv-237-SE Opinion No. 2025 DNH 019 AstraZeneca Pharmaceuticals LP

ORDER

AstraZeneca Pharmaceuticals LP terminated Jack Yvars in 2022 when he did not comply

with its mandatory COVID-19 vaccination policy. Yvars alleges that AstraZeneca violated his

rights under state and federal statute by discriminating against him based on his religion. He also

alleges that AstraZeneca wrongfully terminated him under New Hampshire common law and

improperly withheld his wages. AstraZeneca moves to dismiss the complaint under Rule

12(b)(6) on the basis that it fails to state a claim.

Standard of Review

To survive a Rule 12(b)(6) motion to dismiss for failure to state a claim, a plaintiff must

make factual allegations sufficient to “state a claim to relief that is plausible on its face.”

Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544,

570 (2007)). A claim is facially plausible if it pleads “factual content that allows the court to

draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id.

To test a complaint’s sufficiency, the court must first identify and disregard statements

that “merely offer ‘legal conclusions couched as fact’ or ‘threadbare recitals of the elements of a

cause of action.’” Ocasio–Hernández v. Fortuño-Burset, 640 F.3d 1, 12 (1st Cir. 2011) (quoting

Iqbal, 556 U.S. at 678 (alterations omitted)). Second, the court must credit as true all nonconclusory factual allegations and the reasonable inferences drawn from those allegations,

and then determine if the claim is plausible. See id.

Background

Consistent with this standard of review, the following facts taken from the complaint are

assumed true. Yvars worked for AstraZeneca as a sales representative from October 17, 2011,

until April 29, 2022. In January 2022 during the COVID-19 pandemic, AstraZeneca issued a

mandatory COVID-19 vaccination policy. Under the policy, AstraZeneca said that it would fire

any employee who was not vaccinated against COVID-19 by a certain date, and had not received

a medical, religious, or otherwise applicable exemption. AstraZeneca required employees to

submit any exemption request by February 28, 2022.

On February 21, 2022, Yvars requested a religious exemption to the vaccination policy.

Yvars listed several reasons in support of his request, including because the COVID-19 vaccine

was either made or tested with aborted human fetal cells.

AstraZeneca denied Yvars’s exemption request in an email dated March 31, 2022. The

email gave Yvars until April 22, 2022, to receive his first dose of the COVID-19 vaccine. The

email added that if Yvars failed to do so, AstraZeneca would terminate his employment effective

April 29, 2022.

Yvars asked AstraZeneca to reconsider its decision. He also asked AstraZeneca to engage

in an interactive process to reasonably accommodate his religious beliefs. AstraZeneca

responded that its decision regarding Yvars’s request was final.

Yvars declined to get vaccinated against COVID-19 by April 22, 2022. AstraZeneca

terminated his employment on April 29, 2022. This action followed.

2 Discussion

Yvars’s complaint includes five counts. The first three allege that AstraZeneca violated

Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., and New Hampshire

Revised Statute Annotated (“RSA”) § 354-A by discriminating against Yvars on the basis of his

religion: religious discrimination based on a failure to accommodate (Count I); retaliation based

on religion (Count II); and religious discrimination based on harassment/hostile work

environment (Count III). He also asserts a claim for wrongful discharge under New Hampshire

common law (Count IV), and a claim for wrongful withholding of wages in violation of RSA

275 (Count V).1

AstraZeneca moved to dismiss the complaint in its entirety. After AstraZeneca filed its

motion, Yvars voluntarily dismissed Counts II and III. Doc. no. 18. Also shortly after

AstraZeneca filed its motion, the First Circuit issued Bazinet v. Beth Israel Lahey Health, Inc.,

113 F.4th 9 (1st Cir. 2024). In that case, the First Circuit held that objections on the basis that

COVID-19 vaccines were “developed using fetal cell lines that originated from aborted fetuses”

were sufficient to plead a religious belief that conflicts with a vaccination policy for the purpose

of a Title VII religious discrimination claim at the motion to dismiss stage. Id. at 16. In light of

the Bazinet case, AstraZeneca’s reply withdrew its motion to dismiss as it pertains to Count I.

See doc. no. 14 at 1 n.1. Therefore, the court addresses AstraZeneca’s motion to dismiss as it

relates to Counts IV and V only.

1 Although Count V is titled “Wage Claim NH RSA 279 et seq.,” the allegations supporting that count reference RSA 275. See doc. no. 1-1, ¶ 81. AstraZeneca assumes in its motion to dismiss that Yvars intended to bring a wrongful withholding of wages claim under RSA 275 and moves to dismiss that claim. Yvars confirms in his objection that the reference to RSA 279 in his complaint was an error, and that he is asserting a claim under RSA 275 for the wrongful withholding of his wages. 3 I. Wrongful Discharge (Count IV)

Yvars alleges in Count IV that AstraZeneca wrongfully discharged him because of his

refusal to be vaccinated against COVID-19. A wrongful discharge claim under New Hampshire

law contains two elements: “(1) the employer terminated the [plaintiff’s] employment out of bad

faith, malice, or retaliation; and (2) the employer terminated the employment because the

employee performed acts that public policy would encourage or because she refused to perform

acts that public policy would condemn.” Donovan v. S. New Hampshire Univ., 175 N.H. 489,

492 (2022).

Under New Hampshire law, an “employer’s bad faith or malice may be established where

(i) an employee is discharged for pursuing policies condoned by the employer, (ii) the record

does not support the stated reason for the discharge, or (iii) disparate treatment was administered

to a similarly situated employee.” Hidalgo-Semlek v. Hansa Med., Inc., 498 F. Supp. 3d 236, 268

(D.N.H. 2020) (quotations omitted). “Bad faith can also be discerned from the course of events

surrounding an employee’s discharge, ‘the manner in which the plaintiff was discharged,’ or

shifting reasons for an employee’s termination.” Id. (quoting Cloutier v. Great Atl. & Pac. Tea

Co., 121 N.H. 915, 921 (1981)).

AstraZeneca makes several arguments in favor of dismissal, including that Yvars does

not allege that AstraZeneca fired him out of bad faith, malice, or retaliation. The court agrees

that the complaint contains no allegations that could satisfy this element of a wrongful discharge

claim. The complaint alleges that AstraZeneca implemented the vaccination policy, Yvars did

not comply with the policy and, as a result, AstraZeneca fired him. Yvars alleges no facts that

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Ocasio-Hernandez v. Fortuno-Burset
640 F.3d 1 (First Circuit, 2011)
Cloutier v. Great Atlantic & Pacific Tea Co.
436 A.2d 1140 (Supreme Court of New Hampshire, 1981)

Cite This Page — Counsel Stack

Bluebook (online)
2025 DNH 019, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jack-yvars-v-astrazeneca-pharmaceuticals-lp-nhd-2025.